Pluri Inc. (PLUR) Stock Analysis & Investment Frameworks
Pluri Inc. (PLUR) stock analysis on Invetso. Review Pluri Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pluri Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
Pluri Inc. Key Financial Metrics
- Market Cap: $13.11M
- Revenue: $1.02M
- ROE: 144.63%
- ROIC: -121.13%
- Dividend Yield: N/A
About Pluri Inc.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Pluri Inc. Investment Frameworks
Invetso analyzes Pluri Inc. (PLUR) across the following frameworks:
- Pluri Inc. 10Y Growth Potential
- Pluri Inc. Scenario Analysis
- Pluri Inc. Risks & Opportunities
- Pluri Inc. Economic Moat
- Pluri Inc. Business Model
- Pluri Inc. Management
- Pluri Inc. SWOT Analysis
- Pluri Inc. Porter's 5 Forces
- Pluri Inc. PESTLE Analysis
- Pluri Inc. ESG Analysis